All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · people with unexplained recurrent syncope
It is very uncertain whether summary of findings for the main comparison. Implantable loop recorder changes all‐cause long‐term mortality compared with conventional diagnostic workup (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ long‐term · Anyone diagnosed with AMI
Cells showed no clear difference in all‐cause mortality ‐ long‐term compared with no cells (moderate certainty).
1 finding from 1 review
All‐cause long‐term mortality: 60 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).
1 finding from 1 review
Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review